piracetam has been researched along with Memory Disorders in 46 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
Memory Disorders: Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect of piracetam, a cyclical derivative of GABA, was compared with that of a placebo in a double-blind study of 60 patients with post-concussional syndrome of 2-12 months' duration." | 9.04 | Piracetam in the treatment of post-concussional syndrome. A double-blind study. ( Hakamies, L; Hakkarainen, H, 1978) |
| " This study was designed to compare the effects of levetiracetam, an antiepileptic drug, on memory deficits associated with normal aging and AD in mouse models." | 7.79 | Effects of levetiracetam, an antiepileptic drug, on memory impairments associated with aging and Alzheimer's disease in mice. ( Devi, L; Ohno, M, 2013) |
| "Six patients with idiopathic hemifacial spasm refractory to the usually employed medications were successfully treated with baclofen." | 7.67 | Baclofen in hemifacial spasm. ( Gillman, MA; Sandyk, R, 1987) |
| "Treatment with levetiracetam dose-dependently improved memory performance of the ketamine-exposed rats." | 5.48 | Treatment with levetiracetam improves cognition in a ketamine rat model of schizophrenia. ( Gallagher, M; Koh, MT; Rosenzweig-Lipson, S; Shao, Y, 2018) |
| "The effect of piracetam, a cyclical derivative of GABA, was compared with that of a placebo in a double-blind study of 60 patients with post-concussional syndrome of 2-12 months' duration." | 5.04 | Piracetam in the treatment of post-concussional syndrome. A double-blind study. ( Hakamies, L; Hakkarainen, H, 1978) |
| "A double-blind, intra-individual cross-over comparison of the effect of piracetam on retrograde memory impairement as measured by the KS memory test battery was performed in connection with second and third Bi-ECT in 18 patients diagnosed as suffering from depression." | 5.04 | Does piracetam counteract the ECT-induced memory dysfunctions in depressed patients? ( Cronholm, B; Levander, SE; Mindus, P, 1975) |
| " This study was designed to compare the effects of levetiracetam, an antiepileptic drug, on memory deficits associated with normal aging and AD in mouse models." | 3.79 | Effects of levetiracetam, an antiepileptic drug, on memory impairments associated with aging and Alzheimer's disease in mice. ( Devi, L; Ohno, M, 2013) |
| "Six patients with idiopathic hemifacial spasm refractory to the usually employed medications were successfully treated with baclofen." | 3.67 | Baclofen in hemifacial spasm. ( Gillman, MA; Sandyk, R, 1987) |
| "Forty two had progressed to Alzheimer type dementia during a five year follow up period and were considered to have predementia Alzheimer's disease at baseline." | 2.71 | Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease? ( Scheltens, P; Verhey, FR; Visser, PJ, 2005) |
| " Daily dosage of piracetam was 7." | 2.70 | Effect of piracetam on ECT-induced cognitive disturbances: a randomized, placebo-controlled, double-blind study. ( Leung, HC; Tang, WK; Ungvari, GS, 2002) |
| "Piracetam was found to be well tolerated in this study population." | 2.66 | The effects of piracetam in children with dyslexia. ( Blank, MS; Chase, CH; Conners, CK; Di Ianni, M; Funkenstein, HH; Helfgott, E; Holmes, JM; Lougee, L; Maletta, GJ; Wilsher, CR, 1985) |
| "Treatment with levetiracetam dose-dependently improved memory performance of the ketamine-exposed rats." | 1.48 | Treatment with levetiracetam improves cognition in a ketamine rat model of schizophrenia. ( Gallagher, M; Koh, MT; Rosenzweig-Lipson, S; Shao, Y, 2018) |
| "Piracetam (Pir) is a nootropic drug derived from c-aminobutyric acid and can manage cognition impairments in multiple neurological disorders." | 1.46 | Piracetam inhibits ethanol (EtOH)-induced memory deficit by mediating multiple pathways. ( Feng, J; Wang, J; Xu, F; Yang, Y, 2017) |
| "Dementia is one of the age related mental problems and a characteristic symptom of various neurodegenerative disorders including Alzheimer's disease." | 1.33 | Evaluation of nootropic potential of Ocimum sanctum Linn. in mice. ( Joshi, H; Parle, M, 2006) |
| "Aniracetam was administered to 1-month-old rats, demonstrating a prolonged (2 months) therapeutic effect, observed in rats aged 3 months." | 1.31 | Can nootropic drugs be effective against the impact of ethanol teratogenicity on cognitive performance? ( Vaglenova, J; Vesselinov Petkov, V, 2001) |
| "Memory deficits were induced by the muscarinic cholinoceptor antagonist scopolamine (in young and old rats and mice), by the alpha 2-adrenoceptor agonist clonidine, by electroconvulsive shock, and by hypoxy." | 1.29 | Effects of cytidine diphosphate choline on rats with memory deficits. ( Getova, D; Kehayov, RA; Lazarova, MB; Mosharrof, AH; Petkov, VD; Petkov, VV; Vaglenova, J, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (30.43) | 18.7374 |
| 1990's | 8 (17.39) | 18.2507 |
| 2000's | 7 (15.22) | 29.6817 |
| 2010's | 17 (36.96) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gurjar, AS | 1 |
| Darekar, MN | 1 |
| Yeong, KY | 1 |
| Ooi, L | 1 |
| Havolli, E | 1 |
| Hill, MD | 1 |
| Godley, A | 1 |
| Goetghebeur, PJ | 1 |
| Koh, MT | 3 |
| Shao, Y | 1 |
| Rosenzweig-Lipson, S | 1 |
| Gallagher, M | 3 |
| Yang, Y | 1 |
| Feng, J | 1 |
| Xu, F | 1 |
| Wang, J | 1 |
| Nasr, M | 1 |
| Wahdan, SA | 1 |
| Devi, L | 1 |
| Ohno, M | 1 |
| Marisco, PC | 1 |
| Carvalho, FB | 1 |
| Rosa, MM | 1 |
| Girardi, BA | 1 |
| Gutierres, JM | 1 |
| Jaques, JA | 1 |
| Salla, AP | 1 |
| Pimentel, VC | 1 |
| Schetinger, MR | 1 |
| Leal, DB | 1 |
| Mello, CF | 1 |
| Rubin, MA | 1 |
| Spiegel, AM | 1 |
| Vogt, NM | 1 |
| Rapp, PR | 1 |
| Bugeme, M | 1 |
| Mukuku, O | 1 |
| Wang, YL | 1 |
| Li, F | 1 |
| Chen, X | 1 |
| Wang, PP | 1 |
| Sun, HX | 1 |
| Liu, CJ | 1 |
| Hu, MH | 1 |
| He, XQ | 1 |
| Yue, S | 1 |
| Jiao, ZZ | 1 |
| Xiang, L | 1 |
| Haberman, RP | 1 |
| Sharma, K | 1 |
| Bhatnagar, M | 1 |
| Kulkarni, SK | 1 |
| Halder, S | 1 |
| Mehta, AK | 2 |
| Kar, R | 1 |
| Mustafa, M | 1 |
| Mediratta, PK | 2 |
| Sharma, KK | 1 |
| Kosta, P | 1 |
| Sharma, AK | 1 |
| Khanna, N | 1 |
| Mundhada, DR | 1 |
| Suke, S | 1 |
| Baxter, MG | 1 |
| de Groot, M | 1 |
| Douw, L | 1 |
| Sizoo, EM | 1 |
| Bosma, I | 1 |
| Froklage, FE | 1 |
| Heimans, JJ | 1 |
| Postma, TJ | 1 |
| Klein, M | 1 |
| Reijneveld, JC | 1 |
| Tang, WK | 1 |
| Ungvari, GS | 1 |
| Leung, HC | 1 |
| Yan, R | 1 |
| Nguyen, Q | 1 |
| Gonzaga, J | 1 |
| Johnson, M | 1 |
| Ritzmann, RF | 1 |
| Taylor, EM | 1 |
| Visser, PJ | 1 |
| Scheltens, P | 1 |
| Verhey, FR | 1 |
| Joshi, H | 1 |
| Parle, M | 1 |
| Zhou, JL | 1 |
| Zhao, Q | 1 |
| Holmes, GL | 1 |
| Chen, J | 1 |
| Long, Y | 1 |
| Han, M | 1 |
| Wang, T | 1 |
| Chen, Q | 1 |
| Wang, R | 1 |
| Jolles, J | 1 |
| Verhoeven, WM | 1 |
| Mondadori, C | 1 |
| Schmutz, M | 1 |
| Baltzer, V | 1 |
| Akhundov, RA | 1 |
| Sultanov, AA | 1 |
| Gadzhily, RA | 1 |
| Sadykhov, RV | 1 |
| Trofimov, SS | 2 |
| Ostrovskaia, RU | 1 |
| Kravchenko, EV | 1 |
| Smol'nikova, NM | 1 |
| Bondarenko, NA | 1 |
| Kutepova, OA | 1 |
| Nemova, EP | 1 |
| Voronina, TA | 3 |
| Krylov, IN | 1 |
| Iasnetsov, VV | 1 |
| Dukhanin, AS | 1 |
| Pal'tsev, IuP | 1 |
| Petkov, VD | 2 |
| Kehayov, RA | 1 |
| Mosharrof, AH | 1 |
| Petkov, VV | 1 |
| Getova, D | 1 |
| Lazarova, MB | 2 |
| Vaglenova, J | 2 |
| Israël, L | 1 |
| Myslinski, M | 1 |
| Dubos, G | 1 |
| Mélac, M | 1 |
| Dormehl, IC | 1 |
| Jordaan, B | 1 |
| Oliver, DW | 1 |
| Croft, S | 1 |
| Chang, YH | 1 |
| Hiseh, MT | 1 |
| Wu, CR | 1 |
| Vesselinov Petkov, V | 1 |
| Hakkarainen, H | 1 |
| Hakamies, L | 1 |
| Abuzzahab, FS | 1 |
| Merwin, GE | 1 |
| Zimmermann, RL | 1 |
| Sherman, MC | 1 |
| Holmboe, AM | 1 |
| Mindus, P | 1 |
| Cronholm, B | 1 |
| Levander, SE | 1 |
| Garibova, TL | 1 |
| Sopyev, ZhA | 1 |
| Rakhmankulova, IKh | 1 |
| Gainotti, G | 1 |
| Nocentini, U | 1 |
| Sena, E | 1 |
| Shabanov, PD | 1 |
| Grinenko, AIa | 1 |
| Kalishevich, SIu | 1 |
| Sprints, AM | 1 |
| Sandyk, R | 1 |
| Gillman, MA | 1 |
| Di Ianni, M | 1 |
| Wilsher, CR | 1 |
| Blank, MS | 1 |
| Conners, CK | 1 |
| Chase, CH | 1 |
| Funkenstein, HH | 1 |
| Helfgott, E | 1 |
| Holmes, JM | 1 |
| Lougee, L | 1 |
| Maletta, GJ | 1 |
| Cicerchia, G | 1 |
| Santucci, R | 1 |
| Palmieri, M | 1 |
| Ezzat, DH | 1 |
| Ibraheem, MM | 1 |
| Makhawy, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Network-Level Mechanisms for Preclinical Alzheimer's Disease Development[NCT03461861] | Phase 2 | 26 participants (Actual) | Interventional | 2019-04-11 | Completed | ||
| Brain Changes in Pediatric Obstructive Sleep Apnea[NCT05368077] | 70 participants (Anticipated) | Interventional | 2022-05-14 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The seed-based functional connectivity strengths of the hippocampus network and the default mode network will be employed to measure the changes between AGB101 and Placebo perturbation. The functional connectivity strengths will be measured with the median of the Pearson cross-correlation coefficients over entire brain regions. (NCT03461861)
Timeframe: 2 weeks after treatment between AGB101 and Placebo
| Intervention | Pearson coefficient (Median) |
|---|---|
| AGB101 220 mg | 0.233 |
| Placebo | 0.318 |
Rey Auditory Verbal Learning Test (AVLT), delayed recall Scaled integer will be employed to measure the episodic memory changes before and after AGB101 treatment. The AVLT score will be recorded as a standard score. The theoretical range: min 50, max 155, the higher the better. The higher the number is, the better the memory. It is an integer number. (NCT03461861)
Timeframe: Placebo vs AGB101 2 weeks after treatment paired t-test
| Intervention | score on a scale (Mean) |
|---|---|
| AGB101 220 mg | 108 |
| Placebo | 105 |
2 reviews available for piracetam and Memory Disorders
| Article | Year |
|---|---|
[Neuropsychiatric manifestations revealing cerebral subarachnoid hemorrhage caused by electrification accident about a case and review of literature].
Topics: Accidents, Home; Brain Edema; Child; Child Behavior Disorders; Confusion; Dexamethasone; Electric In | 2014 |
[Psychopharmacologic treatment of cognitive function disorders in aging persons: current possibilities].
Topics: Adrenocorticotropic Hormone; Aged; Alzheimer Disease; Anticonvulsants; Brain; Catecholamines; Cholin | 1984 |
11 trials available for piracetam and Memory Disorders
| Article | Year |
|---|---|
Effect of piracetam on ECT-induced cognitive disturbances: a randomized, placebo-controlled, double-blind study.
Topics: Adult; Depression; Double-Blind Method; Electroconvulsive Therapy; Female; Humans; Male; Memory Diso | 2002 |
Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease?
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Cholinesterase | 2005 |
[Combined therapies in family practice and hospitals. A controlled clinical study of a population of 162 patients with criteria of age-related memory disorders].
Topics: Aged; Aging; Ambulatory Care; Cognitive Behavioral Therapy; Combined Modality Therapy; Double-Blind | 1997 |
SPECT monitoring of improved cerebral blood flow during long-term treatment of elderly patients with nootropic drugs.
Topics: Administration, Oral; Aged; Aging; Brain; Cerebellum; Cerebrovascular Circulation; Cognition; Cross- | 1999 |
Piracetam in the treatment of post-concussional syndrome. A double-blind study.
Topics: Brain Concussion; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Fatigue; Headache; | 1978 |
A double blind investigation of piracetam (Nootropil) vs placebo in geriatric memory.
Topics: Aged; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Intelligence Tests; Male; Memor | 1977 |
Does piracetam counteract the ECT-induced memory dysfunctions in depressed patients?
Topics: Adult; Aged; Clinical Trials as Topic; Depression; Drug Evaluation; Electroconvulsive Therapy; Femal | 1975 |
Can the pattern of neuropsychological improvement obtained with cholinergic drugs be used to infer a cholinergic mechanism in other nootropic drugs?
Topics: Alzheimer Disease; Clinical Trials as Topic; Cognition; Cognition Disorders; Double-Blind Method; Hu | 1989 |
The effects of piracetam in children with dyslexia.
Topics: Adolescent; Child; Clinical Trials as Topic; Depression; Dyslexia; Humans; Male; Memory Disorders; M | 1985 |
[Use of piracetam in the treatment of cranial injuries. Observations on 903 cases].
Topics: Adolescent; Adult; Aged; Brain Concussion; Child; Child, Preschool; Clinical Trials as Topic; Consci | 1985 |
The effect of Piracetam on ECT--induced memory disturbances.
Topics: Adolescent; Adult; Clinical Trials as Topic; Depressive Disorder; Electroconvulsive Therapy; Female; | 1985 |
33 other studies available for piracetam and Memory Disorders
| Article | Year |
|---|---|
In silico studies, synthesis and pharmacological evaluation to explore multi-targeted approach for imidazole analogues as potential cholinesterase inhibitors with neuroprotective role for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; | 2018 |
Spatial recognition test: A novel cognition task for assessing topographical memory in mice.
Topics: Alzheimer Disease; Animals; Cognition; Disease Models, Animal; Donepezil; Indans; Levetiracetam; Mal | 2017 |
Treatment with levetiracetam improves cognition in a ketamine rat model of schizophrenia.
Topics: Amphetamine; Animals; Central Nervous System Stimulants; Cognition Disorders; Disease Models, Animal | 2018 |
Piracetam inhibits ethanol (EtOH)-induced memory deficit by mediating multiple pathways.
Topics: Alcohol-Related Disorders; Animals; Apoptosis; Cell Line; Cell Survival; Dose-Response Relationship, | 2017 |
Neuroprotective effects of novel nanosystems simultaneously loaded with vinpocetine and piracetam after intranasal administration.
Topics: Administration, Intranasal; Animals; Brain; Drug Compounding; Drug Delivery Systems; Male; Maze Lear | 2019 |
Effects of levetiracetam, an antiepileptic drug, on memory impairments associated with aging and Alzheimer's disease in mice.
Topics: Aging; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Conditioning, Operant; Disease Mo | 2013 |
Piracetam prevents scopolamine-induced memory impairment and decrease of NTPDase, 5'-nucleotidase and adenosine deaminase activities.
Topics: 5'-Nucleotidase; Adenosine; Adenosine Deaminase; Adenosine Triphosphate; Animals; Behavior, Animal; | 2013 |
Hilar interneuron vulnerability distinguishes aged rats with memory impairment.
Topics: Aging; Animals; Antigens, Nuclear; Behavior, Animal; CA3 Region, Hippocampal; Cell Count; Cognition; | 2013 |
Piracetam prevents memory deficit induced by postnatal propofol exposure in mice.
Topics: Animals; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cyclic AMP-Dependent Protein Kinases; D | 2016 |
Racemic oleracein E increases the survival rate and attenuates memory impairment in D-galactose/NaNO₂-induced senescent mice.
Topics: Alkaloids; Animals; Antioxidants; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cognition; Cogni | 2016 |
Heightened cortical excitability in aged rodents with memory impairment.
Topics: Animals; CA3 Region, Hippocampal; Cerebral Cortex; Cognition; Disease Models, Animal; Levetiracetam; | 2017 |
Effect of Convolvulus pluricaulis Choisy and Asparagus racemosus Willd on learning and memory in young and old mice: a comparative evaluation.
Topics: Acetylcholine; Aging; Animals; Antioxidants; Cholinergic Agents; Convolvulus; Dose-Response Relation | 2010 |
Clove oil reverses learning and memory deficits in scopolamine-treated mice.
Topics: Animals; Brain; Clove Oil; Cognition Disorders; Glutathione; Lipid Peroxidation; Male; Malondialdehy | 2011 |
Effect of piracetam and vitamin E on phosphamidon-induced impairment of memory and oxidative stress in rats.
Topics: Animals; Avoidance Learning; Cognition; Lipid Peroxidation; Male; Memory Disorders; Neuroprotective | 2013 |
Quieting the overactive hippocampus restores memory in aging.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Cognitive Dysfunction; Hippocampus; Humans; Levetir | 2012 |
Levetiracetam improves verbal memory in high-grade glioma patients.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Brain Neoplasms; Cognition Disorders; Female; Glioma; Huma | 2013 |
Reversal of cycloheximide-induced memory disruption by AIT-082 (Neotrofin) is modulated by, but not dependent on, adrenal hormones.
Topics: Adrenalectomy; Aldosterone; Aminobenzoates; Animals; Behavior, Animal; Corticosterone; Cycloheximide | 2003 |
Evaluation of nootropic potential of Ocimum sanctum Linn. in mice.
Topics: Alzheimer Disease; Amnesia; Animals; Dementia; Diazepam; Dose-Response Relationship, Drug; Humans; M | 2006 |
Effect of levetiracetam on visual-spatial memory following status epilepticus.
Topics: Animals; Anticonvulsants; Behavior, Animal; Cell Death; Disease Models, Animal; Electroencephalograp | 2007 |
Water-soluble derivative of propolis mitigates scopolamine-induced learning and memory impairment in mice.
Topics: Acetylcholinesterase; Animals; Arginine; Cerebral Cortex; Chromatography, High Pressure Liquid; Hipp | 2008 |
Potentiation of the anticonvulsant effects of antiepileptic drugs by "nootropics"; a potential new therapeutic approach.
Topics: Animals; Anticonvulsants; Carbamazepine; Clonazepam; Dose-Response Relationship, Drug; Drug Synergis | 1984 |
[Psychoregulating role of nicotinamide].
Topics: Amnesia; Animals; Anti-Anxiety Agents; Anticonvulsants; Male; Memory Disorders; Mice; Neurotic Disor | 1993 |
[Behavior disorders in rats exposed to intrauterine hypoxia, and their correction by postnatal treatment with piracetam].
Topics: Animals; Behavior, Animal; Female; Fetal Hypoxia; Learning Disabilities; Memory Disorders; Piracetam | 1993 |
[Pharmacologic correction of learning and memory disorders induced by exposure to high-frequency electromagnetic radiation].
Topics: Animals; Learning Disabilities; Male; Memory Disorders; Microwaves; Naloxone; Piracetam; Psychotropi | 1993 |
Effects of cytidine diphosphate choline on rats with memory deficits.
Topics: Aging; Animals; Avoidance Learning; Clonidine; Cytidine Diphosphate Choline; Electroshock; Fetal Alc | 1993 |
Effects of acupuncture at pai-hui on the deficit of memory storage in rats.
Topics: Acupuncture Points; Animals; Avoidance Learning; Combined Modality Therapy; Cycloheximide; Electrosh | 1999 |
Can nootropic drugs be effective against the impact of ethanol teratogenicity on cognitive performance?
Topics: Alcohol-Induced Disorders, Nervous System; Animals; Disease Models, Animal; Female; Learning Disabil | 2001 |
[Nootropyl (piracetam)--memory disorders].
Topics: Humans; Memory Disorders; Piracetam; Pyrrolidinones | 1977 |
Comparative studies on the influence of ONK (N(5-hydroxynicotinoil) glutamic acid), piracetam and meclofenoxate on the learning- and memory-impairing effect of scopolamine, clonidine, and methergoline.
Topics: Animals; Avoidance Learning; Clonidine; Glutamates; Learning Disabilities; Male; Meclofenoxate; Memo | 1991 |
[Pharmacological analysis of memory disorders of different origins].
Topics: Amnesia; Animals; Anti-Anxiety Agents; Avoidance Learning; Benzodiazepines; Benzodiazepinones; Condi | 1989 |
[Use of preparations from the nootropic group for treating memory disorders in chronic alcoholism].
Topics: Adult; Alcoholism; Drug Evaluation; Etimizol; Humans; Imidazoles; Memory; Memory Disorders; Piraceta | 1988 |
[The mechanisms of memory disorders at the stages in its acquisition and fixation].
Topics: Amnesia; Animals; Avoidance Learning; Conditioning, Classical; Dose-Response Relationship, Drug; Fem | 1988 |
Baclofen in hemifacial spasm.
Topics: Adult; Baclofen; Facial Muscles; Female; Humans; Male; Memory Disorders; Middle Aged; Piracetam; Spa | 1987 |